Blood diseases span a wide spectrum — from common anemias and bleeding disorders to complex hematologic malignancies such as leukemia, lymphoma and multiple myeloma. Foshan Chancheng Hospital's Precision Oncology Services covers the full range, backed by a multidisciplinary team (MDT) that brings together hematologists, medical oncologists, radiation oncologists, radiologists and pathologists.

For patients with relapsed or refractory disease, we offer advanced cellular therapies including CAR-T, together with novel targeted and antibody treatments made available through the Guangdong-Hong Kong-Macao "Medicine and Device Link".

Common Blood Diseases

From everyday anemias to rare bleeding disorders and hematologic malignancies.

🩸

Anemias

Genetic anemias (e.g. thalassemia), nutritional anemias (iron, B12 or folate deficiency), hemolytic anemias (autoimmune, PNH) and aplastic anemia. PNH is a rare disease — new therapies are available at our hospital.

🩹

Bleeding Disorders

Immune thrombocytopenia (ITP) and hemophilia, an X-linked recessive rare bleeding disorder. Our hospital has established a multidisciplinary team for hemophilia with full-cycle management meeting hemophilia-center standards.

🧬

Hematologic Malignancies

Leukemia, lymphoma and multiple myeloma — treated with chemotherapy, targeted therapy, immunotherapy and cellular therapy within an integrated oncology program.

Leukemia & Targeted Therapy

According to the CSCO malignant hematology guidelines (2022), leukemia is classified into myeloid (AML, CML) and lymphoid (ALL, CLL) types. Tyrosine-kinase inhibitors (TKIs) are the cornerstone of Ph+ ALL and CML — imatinib markedly extended survival, while later generations (dasatinib, nilotinib) and the third-generation ponatinib address treatment resistance.

Our center was the first and only in mainland China to introduce ponatinib through the Guangdong-Hong Kong-Macao "Medicine and Device Link".

🧪

Lymphoma & Multiple Myeloma

Diffuse large B-cell lymphoma (DLBCL) is the most common Non-Hodgkin lymphoma — about 25–50% worldwide and roughly 36–40.8% of Chinese NHL cases, with an incidence of ~5.6 per 100,000 and mortality of ~1.8 per 100,000. Multiple myeloma is another key plasma-cell malignancy we treat.

⚠

The Challenge of Relapsed / Refractory Disease

Patients with relapsed or refractory DLBCL have a poor prognosis. In the SCHOLAR-1 study, event-free survival fell to ~0.11 by 12 years; the REAL-TREND Chinese real-world study reported ORR 30%, CR 9%, median OS 5.9 months and 2-year OS 16% after salvage therapy.

CAR-T Cell Therapy — A Scientific Breakthrough

Chimeric antigen receptor T-cell therapy reprograms a patient's own immune cells to fight cancer.

CAR-T (chimeric antigen receptor T-cell) therapy collects a patient's T cells, engineers them to recognize a cancer-specific antigen, expands them, and infuses them back. Recognized by Science as the 2013 Breakthrough of the Year, cellular immunotherapy is now considered the fourth pillar of cancer treatment — after surgery, radiotherapy and chemotherapy.

💉

1 · Collect

Leukapheresis separates white blood cells from the patient's blood.

🧬

2 · Isolate & Activate

T cells are isolated and activated for genetic engineering.

🧪

3 · Genetic Modification

A viral vector introduces the chimeric antigen receptor (CAR) gene.

📈

4 · Expand

CAR-T cells are multiplied to therapeutic numbers.

🩺

5 · Infuse

The engineered CAR-T cells are infused back to attack the cancer.

Axi-cel Global Approvals

October 2017 — US FDA approves Axi-cel for relapsed/refractory large B-cell lymphoma after two or more lines of therapy.
August 2018 — European Commission approves Axi-cel for relapsed/refractory DLBCL and PMBCL.
February 2019 — Health Canada approves Axi-cel for relapsed/refractory LBCL.
January 2021 — Japan PMDA approves Axi-cel for relapsed/refractory LBCL.
March 2021 — US FDA approves Axi-cel for relapsed/refractory follicular lymphoma.
June 2021 — China NMPA approves Axi-cel for relapsed/refractory LBCL after two or more lines.
April 2022 — US FDA approves Axi-cel for first-line refractory or relapse within 12 months.
June 2023 — China CDE approves the second-line indication.

Our CAR-T Program

Guideline-driven, multidisciplinary and built around each patient.

📚

CSCO-Guided Care

Per the CSCO CAR-T guidelines (2022): CAR-T is a Level I recommendation for adult LBCL after two or more lines; Level II for primary-refractory or early-relapse LBCL; Level III for follicular lymphoma after two or more lines.

🤝

Multidisciplinary MDT

Every CAR-T case is reviewed by an MDT — "it takes a village": hospital leadership support, rigorous training and drills, and seamless cross-department collaboration.

⚖

Bridge & Consolidation

Bridging radiotherapy and other therapies are used to control disease before and after CAR-T, improving outcomes and deepening responses.

Case Study — Toward a Cure

A 46-year-old woman (Ms. Liang) was diagnosed with high-grade B-cell lymphoma (MYC/BCL6 rearrangement, stage IV). After multiple lines of therapy with repeated relapse, she received CAR-T following bridging precision radiotherapy — and achieved her first complete remission (CR). PET-CT at three months showed a complete metabolic response.

🧪

Tafasitamab

An Fc-enhanced humanized anti-CD19 monoclonal antibody. In the L-MIND study for relapsed/refractory DLBCL, ORR reached 57.5%, CR 40.0%, median OS 33.5 months and median duration of response 43.9 months — superior to existing regimens, with manageable safety.

🧬

Equecabtagene (BCMA CAR-T)

The world's first fully human BCMA-targeted CAR-T therapy, approved for adults with relapsed/refractory multiple myeloma after three or more lines — delivering rapid, deep and durable responses and extending survival, with controllable safety.

Hematology & CAR-T Cell Therapy